Segment Information (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Schedule of Segment Information

Revenue, direct costs, and contribution margin for each of the Company's segments were as follows (in thousands):

	Three Months Ended March 31,
	2017		2016
Revenue:
Clinical Development Services	$	249,727	$	245,973
Phase I Services	2,351		3,024
Segment revenue	252,078		248,997
Reimbursable out-of-pocket expenses not allocated to segments	129,840		164,090
Total revenue	$	381,918	$	413,087
Direct costs:
Clinical Development Services	$	152,620	$	149,314
Phase I Services	2,215		2,744
Segment direct costs	154,835		152,058
Reimbursable out-of-pocket expenses not allocated to segments	129,840		164,090
Direct costs and reimbursable out-of-pocket expenses	$	284,675	$	316,148
Segment contribution margin:
Clinical Development Services	$	97,107	$	96,659
Phase I Services	136		280
Segment contribution margin	97,243		96,939
Less expenses not allocated to segments:
Selling, general, and administrative	44,934		43,479
Restructuring, CEO transition and other costs	1,927		6,038
Transaction expenses	2		561
Depreciation and amortization	15,628		14,353
Consolidated income from operations	$	34,752	$	32,508